Control Bionics Limited
Control Bionics Limited
Your view on CBL.AX
Overview
What the company does, where it operates, and who runs it.
About Control Bionics Limited
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Jeremy E. Steele
- Headquarters
- 11-13 Pearson Street, Cremorne, VIC, AU
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Jeremy E. Steele
- Headquarters
- 11-13 Pearson Street, Cremorne, VIC, AU
Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Control Bionics Limited, and the rating behind it. CBL.AX last traded at AUD 0.07; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Control Bionics Limited. Starting points for Control Bionics Limited: EPS -AUD 0.02, beta 0.10 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Control Bionics Limited. Control Bionics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Control Bionics Limited. Trailing twelve-month EPS for Control Bionics Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Control Bionics Limited. Control Bionics Limited has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Control Bionics Limited valued side by side against its closest peers. Control Bionics Limited is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Control Bionics Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Control Bionics Limited executives and directors. Shares of Control Bionics Limited have traded between AUD 0.03 and AUD 0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Control Bionics Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Control Bionics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Control Bionics Limited. Coverage tracks Control Bionics Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.